510(k) device
MR Q
Meridian AG · Laser, Ophthalmic (HQF, Class II) · First FDA decision Jan 25, 2024, newest Jan 25, 2024GlaucomaMacular degeneration and retinal disease
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
510(k) pathway
Device trials
2
Naming "MR Q"
MAUDE reports
0
Brand "MR Q", since 2015
PubMed studies
12
Mentioning "MR Q"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing MR Q
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
K232417 · Decided Jan 25, 2024 · 167 days after receipt
Device type: Laser, Ophthalmic (HQF) · Ophthalmology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "MR Q", any status and sponsor, newest update first.
Dana-Farber Cancer InstituteAcademic, hospital or other
NCT03993210 · 1 participants · Start Sep 18, 2019 · Primary completion Sep 19, 2019
Device: Magnetic Resonance Fingerprinting (MRF); Q-space Trajectory Imaging (QTI) and 1 more · For: Gynecologic Tumor
Sites: Boston, Massachusetts · 2 sites in all
GE HealthcarePublic (GEHC)
NCT02927327 · 61 participants · Start Nov 2016 · Primary completion Sep 20, 2017
Device: Zero Echo Time (ZTE) scan for head attenuation; Q.Static (Q. MRAC) for respiratory motion correction · For: Brain Imaging; Whole Body Imaging
Sites: Rochester, Minnesota
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "MR Q", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code HQF
1,026 reports: 790 malfunction, 231 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "MR Q"[tiab]. The summary above synthesizes these.
- A 42-year-old man considering whether to drink alcohol for his health.
Mukamal KJ · JAMA · 2010Clinical Conference
- Where, what, why: Mr. Q on the Web.
Ammann A, Kiss T, Hirsch M, et al. · Int J Comput Dent · 2008
- Helium-3 MR q-space imaging with radial acquisition and iterative highly constrained back-projection.
O'Halloran RL, Holmes JH, Wu YC, et al. · Magn Reson Med · 2010Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- The effect of Q.Clear reconstruction on quantification and spatial resolution of 18F-FDG PET in simultaneous PET/MR.
Tian D, Yang H, Li Y, et al. · EJNMMI Phys · 2022
- Metabolic cold adaptation contributes little to the interspecific variation in metabolic rates of 65 species of Drosophilidae.
Messamah B, Kellermann V, Malte H, et al. · J Insect Physiol · 2017Research Support, Non-U.S. Gov't
- The Bidirectional Relationship Between Gastroesophageal Reflux Disease (GERD) and Asthma in Pediatric and Adult Populations: A Systematic Review.
Hamed NF, AlAlwan AA, Alqahtani FJ, et al. · Cureus · 2025Review
- MR Quantification of Flow in Children with Vascular Malformations.
Poskitt KJ, Marotta T, Haw C, et al. · Interv Neuroradiol · 2001
- Soil respiration fluxes in a temperate mixed forest: seasonality and temperature sensitivities differ among microbial and root-rhizosphere respiration.
Ruehr NK, Buchmann N · Tree Physiol · 2010Research Support, Non-U.S. Gov't
- Echocardiographic indices and severity of mitral regurgitation in dogs with preclinical degenerative mitral valve disease.
Larouche-Lebel É, Loughran KA, Oyama MA · J Vet Intern Med · 2019
- Management of intractable nausea and vomiting in patients at the end of life: "I was feeling nauseous all of the time . . . nothing was working".
Wood GJ, Shega JW, Lynch B, et al. · JAMA · 2007Case Reports, Research Support, Non-U.S. Gov't
- A placebo-controlled study investigating the efficacy and safety of the phosphodiesterase type 5 inhibitor UK-369,003 for the treatment of men with lower urinary tract symptoms associated with clinical benign prostatic hyperplasia.
Tamimi NA, Mincik I, Haughie S, et al. · BJU Int · 2010Multicenter Study, Randomized Controlled Trial
- Conversations with consultants. Mr Q the surgeon. Interview by Tony Smith.
Smith T · Br Med J (Clin Res Ed) · 1988Interview
Other devices of this type
Also filed under product code HQF.
- Hyperion Ltk SystemSunrise Technologies, Inc. · PMA 2002
- Sunrise Technologies Hyperion(Tm) Holmium Laser System for Laser Thermal Keratoplasty (Ltk)Sunrise Technologies, Inc. · PMA 2001
- Navilas Laser System 577sl (156691)Od-Os GmbH · 510(k) 2025
- VISULAS greenCarl Zeiss Meditec · 510(k) 2023
- Iridex 810 LaserIridex Corporation · 510(k) 2022
- Ophthalmic Yag Laser System YC-200Nidek Co., Ltd. · 510(k) 2020
- PSLT with PASCAL Synthesis, PSLT with PASCAL Synthesis TwinStarTopcon Medical Laser Systems, Inc. · 510(k) 2018
- LightLas Multi-Wavelength Medical Laser SystemLightmed Corporation · 510(k) 2016
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.